Native, pro-resolutive complement modulation via Factor H

In complement disorders, the approved treatments today work by inactivating this crucial part of our body’s immune system very broadly leaving patients more vulnerable to infections. The Eleva solution has the potential to restore the natural balance in the complement system, thereby controlling over-activation while retaining its protective properties.

Eleva is developing Factor H (CPV-104), a recombinant version of human complement Factor H, with a primary focus on delivering clinical data in C3 Glomerulopathy (C3G) as the lead indication. Beyond C3G, the program has shown therapeutic potential in a range of indications including atypical hemolytic uremic syndrome (aHUS) and the dry form of age-related macular degeneration (dry AMD).

C3G represents a rare renal disease caused by the dysfunction of the complement system. In C3G patients, deposits of the complement factor C3 in the kidneys represent the main driver of impaired organ function and potentially organ failure requiring transplantation.

Eleva has delivered positive preclinical results for Factor H (CPV-104) including in vivo data using an established animal model for C3G. Amongst other positive findings, treatment with Factor H (CPV-104) resulted in normalization of serum C3 levels within 24 hours after injection and the rapid degradation of C3 deposits in the kidney.

The company is preparing a first clinical study in C3G and expects to commence dosing the first patients in H1 2025.